UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~May ~~2021~~2022

Commission File Number: 001- 39167

Molecular Data Inc.

11/F, Building 15, 2177 Shenkun Road

Minhang District, Shanghai 201106

People’s Republic of China
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Explanatory Note:

On ~~November~~May 2917, ~~2021~~2022, ~~the~~Molecular ~~NASDAQ~~Data ~~Stock~~Inc. ~~Market~~ (~~“NASDAQ~~the ”Company”) ~~granted~~received ~~Molecular~~a ~~Data~~letter ~~Inc.~~ (the “~~Company~~Letter”) anfrom ~~additional~~The ~~180~~Nasdaq ~~calendar~~Stock ~~days,~~Market orLLC ~~until~~(“Nasdaq”) ~~May~~stating ~~23,~~that ~~2022,~~since tothe ~~regain~~Company ~~compliance~~has ~~with~~not ~~the~~yet ~~$1.00~~filed ~~per~~its ~~share~~Form ~~minimum~~20-F for ~~required~~the ~~for~~year ~~continued listing~~ended onDecember ~~The~~31, ~~NASDAQ~~2021 ~~Capital~~(the ~~Market~~“Filing”), ~~pursuant~~it tono ~~NASDAQ~~longer ~~Marketplace~~complies ~~Rule~~with ~~5550(a)(2)~~Nasdaq Listing Rules (the “~~Minimum~~Rules”) for ~~Bid~~continued ~~Price~~listing under Listing Rule” 5250(c)(1).

AsUnder previously reported, on May 25, 2021, the Company received a notification letter (the “Notice”) from NASDAQ advising the Company that for 30 consecutive business days preceding the date of the Notice, the bid price of the CompanyNasdaq’s ~~common stock~~Rules ~~had closed below~~ the ~~$1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to the Minimum Bid Price Rule. The~~ Company ~~was~~now ~~provided~~has ~~180~~60 calendar days, ~~or until November 22, 2021,~~ to ~~regain~~submit ~~compliance~~a ~~with~~plan ~~the Minimum Bid Price Rule. The Company was unable~~ to regain compliance ~~with~~and ~~the~~if ~~Minimum~~Nasdaq ~~Bid~~accepts ~~Price Rule by November 22, 2021. The NASDAQ determination to grant~~ the ~~second compliance period was based on the~~ Company’s ~~meeting the continued listing requirement for market value of publicly~~ ~~held shares and other applicable requirements for initial listing on The NASDAQ Capital Market~~plan, ~~with~~Nasdaq ~~the~~can ~~exception~~grant of the ~~bid price requirement, and the~~ Company’s ~~written~~an ~~notice~~exception of ~~its~~up ~~intention~~ to ~~cure~~180 ~~the~~calendar ~~deficiency~~days ~~during~~from the ~~second~~Filing’s ~~compliance~~due ~~period~~date, byor ~~effecting~~until aNovember ~~reverse stock~~14, ~~split~~2022, to ifregain ~~necessary~~compliance.

ToThe ~~regain compliance, the bid price of the~~ Company’s ~~common~~shall ~~stock~~email ~~must~~its ~~close~~plan ~~at or above $1.00 per share for a minimum of ten consecutive business days at any time during the second 180-day compliance period. The Company intends~~ to ~~monitor~~Nasdaq ~~the~~no ~~closing~~later ~~bid~~than ~~price~~July ~~of its common stock and may~~18, ~~if appropriate, consider implementing available options, including effecting a reverse stock split~~2022. ~~There~~If ~~can~~Nasdaq bedoes nonot ~~assurance that~~accept the Company’s ~~will~~plan, ~~be able to regain compliance with~~ the ~~Minimum~~Company ~~Bid Price Rule or maintain compliance with the other listing requirements~~will ~~necessary~~have ~~for~~ the ~~Company~~opportunity to ~~maintain~~appeal ~~the~~that ~~listing~~decision ofto ~~its~~a ~~common~~Hearings ~~stock on The NASDAQ Capital Market~~Panel.

The ~~Notice~~Letter has no effect on the listing of the Company’s shares at this time and the Company’s ~~common~~American ~~stock~~Depositary ~~will~~Shares will continue to trade on The ~~NASDAQ~~Nasdaq Capital Market under the symbol “MKD.”

Exhibits

Exhibit 99.1

Press release dated May 19, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Molecular Data Inc.

By	:	/s/ Steven Foo
Name	:	Steven Foo
Title	:	Chief Executive Officer and Chief Financial Officer

Date: ~~November~~May 3019, ~~2021~~2022

Filing Compare · Molecular Data Inc.